valsartan

19 Oct: Hypertention Drug Valturna combines Diovan & Tekturna in a single pill

A new blood-pressure treatment has come on the market that is of potential interest to hypertension patients whose blood pressure is not being adequately controlled with monotherapy. Last month, the US Food and Drug Administration (FDA) approved Novartis’ Valturna (aliskiren and valsartan), which combines in a single pill valsartan, the active ingredient in Diovan, the top-selling branded high blood pressure medicine and aliskiren, the active ingredient in Tekturna — the only approved direct renin inhibitor (DRI). Valturna is the first and only medicine to target two key points within the renin system, an important regulator of blood pressure. It is suitable for patients whose high blood pressure has not been adequately controlled on aliskiren alone, or by an angiotensin receptor blocker, such as…